This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Owens & Minor (OMI) Q4 Earnings Expected to Decline
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Owens & Minor (OMI) Meets Q3 Earnings Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 0.00% and -3.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Q2 Earnings Lag Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of -30.43% and 0.24%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Choose Owens & Minor (OMI) Stock?
by Zacks Equity Research
Owens & Minor (OMI) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.
New Strong Sell Stocks for December 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Graham-Cassidy Fail Shines Spotlight on 3 Top Dividend Stocks
by Zacks Equity Research
Zeroing in on dividend stocks with a solid Zacks Rank is a great way to increase the chances of beating volatile market conditions while ensuring a steady stream of cash flow. Here are three top picks in the MedTech space.
Can Owens & Minor (OMI) Prove to be Suitable Value Pick?
by Zacks Equity Research
Let's find out if Owens & Minor, Inc. (OMI) stock is a good choice for value-oriented investors right now
Edwards Lifesciences Pipeline Impressive, Currency Woes Stay
by Zacks Equity Research
Edwards Lifesciences (EW) rides high on product launches as well as strength in the global Transcatheter Aortic Valve Replacement market.
Quest Diagnostics to Buy Shiel to Widen Footprint in NY-NJ
by Zacks Equity Research
After the completion of Shiel's acquisition, the medical lab is expected to expand Quest Diagnostics' (DGX) physician and patient service centers network in the New York-New Jersey area.
Top Ranked Momentum Stocks to Buy for October 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 2nd:
Top Ranked Income Stocks to Buy for October 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 2nd:
Top Ranked Income Stocks to Buy for September 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 15th:
5 Discounted MedTech Stocks for a Healthy Portfolio
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these five MedTech stocks stand out as the most suitable value picks.
4 Top MedTech Stocks for Dividend Investors in 2017
by Zacks Equity Research
Dividend stocks are always investors' preferred choice as they provide steady income and cushion against market risks.
Is Owens & Minor (OMI) Stock A Great Combo of Value and Growth?
by Zacks Equity Research
Owens & Minor (OMI) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Top Ranked Income Stocks to Buy for September 1st
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 1st:
Orthofix (OFIX) is a Great Momentum Pick for You: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, Orthofix (OFIX) stands out as one of the most suitable momentum stock.
Top Ranked Income Stocks to Buy for August 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 22nd:
What Falling Estimates & Price Mean for Abaxis (ABAX)
by Zacks Equity Research
Abaxis (ABAX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Top Ranked Income Stocks to Buy for August 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 14th:
Medical Product Q1 Earnings Due on May 2: BDX, DXCM & More
by Zacks Equity Research
The medical product sector shines bright at the moment owing to the prevalence of minimally invasive surgeries, liquid biopsy tests, and use of IT for ensuring quick and improved patient care among other things.
Owens & Minor (OMI) Reaffirms Tepid 2017 Financial Guidance
by Zacks Equity Research
Owens & Minor Inc. (OMI) outlined its new strategic plan and reaffirmed the financial guidance.
5 Easy Money Stocks to Buy
by David Bartosiak
Zacks Rank Plus Momentum Stocks Equals Easy Money